Table 1. Baseline patient characteristics.
| Characteristic | N=54 (%) |
|---|---|
| Male (n, %) | 45 (83.3) |
| Age, years, median (range) | 57.5 (27–72) |
| ECOG performance | |
| 0–1 | 54 (100) |
| Tumour differentiation | |
| Well differentiated | 2 (3.7) |
| Moderately differentiated | 27 (50.0) |
| Poorly differentiated | 20 (37.0) |
| Signet ring cell cancer | 5 (9.3) |
| Site of metastasis | |
| Liver | 27 (50.0) |
| Peritoneum | 12 (22.2) |
| Abdominal lymph node | 40 (74.1) |
| Ovary | 3 (5.6) |
| Bone | 1 (1.9) |
| Lung | 2 (3.7) |
| Left supraclavicular lymph node | 4 (7.4) |
| Othersa | 2 (3.7) |
| Prior gastrectomy | 23 (42.6) |
| Adjuvant chemotherapy | 15 (27.7) |
| Prior chemotherapy | |
| Fluoropyrimidine | 52 (100) |
| Platinum | 52 (100) |
| Docetaxel | 19 (35.2) |
| Irinotecan | 2 (3.7) |
Abbreviation: ECOG=Eastern Cooperative Oncology Group.
a
Other site: adrenal gland (n=1), psoas muscle (n=1).